Prelude Therapeutics Inc Stock Price, News & Analysis

Prelude Therapeutics (Nasdaq: PRLD) announced the appointment of Dr. Jane Huang as President and Chief Medical Officer, effective April 4, 2022. Dr. Huang brings extensive experience in oncology drug development, previously serving as Chief Medical Officer at BeiGene. CEO Kris Vaddi highlighted her strategic leadership as crucial for advancing Prelude’s precision oncology pipeline, which focuses on underserved cancers. Prelude is developing several promising drug candidates, including PRT543, PRT811, PRT1419, and PRT2527, targeting critical cancer cell pathways.

Prelude Therapeutics Inc. (NASDAQ: PRLD) announced that CEO Kris Vaddi, PhD, will present virtually at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022, at 1:40 p.m. ET. A live webcast can be accessed through the company's Investors page, with a replay available afterwards.

Prelude is a clinical-stage precision oncology company developing innovative treatments targeting critical cancer cell pathways. Their candidates include PRT543, PRT811, PRT1419, and PRT2527, focusing on various malignancies.

Prelude Therapeutics Inc. (Nasdaq: PRLD) announced that CEO Kris Vaddi, PhD, will present at the H.C Wainwright BioConnect Virtual Conference from January 10-13, 2022. The prerecorded presentation will be available on January 10, 2022, at 7:00 am ET on the company's Investors page. Prelude is a clinical-stage precision oncology company focusing on developing innovative cancer treatments, including PRMT5 inhibitors and MCL1 inhibitors in Phase 1 development. The company is advancing several pipelines aimed at targeting critical cancer cell pathways.

Prelude Therapeutics Inc. (Nasdaq: PRLD) announced that CEO Kris Vaddi, PhD, will speak at the 4th Annual Evercore ISI HealthCONx Conference on December 1, 2021, at 9:15 am ET. A live webcast and replay will be available on Prelude's 'Investors' page. The company focuses on developing precision oncology molecules targeting cancer pathways. Its candidates include PRT543 and PRT811 for solid tumors, CNS cancers, and myeloid malignancies, along with PRT1419 and PRT2527 for hematologic malignancies and solid tumors. Other promising projects are also in the pipeline.

Prelude Therapeutics (Nasdaq: PRLD) reported third-quarter 2021 financial results, revealing a net loss of $30.7 million, or $0.66 per share, compared to a $16.8 million loss in Q3 2020. The company holds a strong cash position of $320.9 million to support its clinical pipeline. Notable updates include favorable data from Phase 1 trials for PRMT5 inhibitors PRT543 and PRT811, which showed good tolerability and preliminary clinical activity. Additionally, PRT2527's IND was cleared by the FDA, with a Phase 1 trial anticipated by year-end.

Prelude Therapeutics announced that the FDA has accepted its IND application for PRT2527, a selective CDK9 inhibitor. A Phase 1 clinical trial is expected to begin by year-end, targeting solid tumors like sarcoma and breast cancer. Preclinical studies show PRT2527 effectively reduces MYC and MCL1 protein levels, hinting at promising efficacy and safety. Prelude's CEO expressed confidence in its oncology development pipeline, aiming to provide new treatment options for challenging cancers.

Prelude Therapeutics (Nasdaq: PRLD) recently announced promising data from its Phase 1 trials of oral PRMT5 inhibitors PRT543 and PRT811, which showed favorable safety profiles and preliminary clinical activity with durable responses in various tumors. Specifically, PRT543 achieved a 69% reduction in serum sDMA and demonstrated a durable complete response in a patient with HRD+ ovarian cancer. PRT811 exhibited an 83% reduction in serum sDMA, with notable responses in patients with high-grade gliomas and uveal melanoma. Additionally, preclinical studies indicated PRT2527's efficacy in hematological malignancies.

Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology firm, announced its participation in two virtual investor conferences. The first will be at the Morgan Stanley 19th Annual Global Healthcare Conference on September 9, 2021, at 11:45 a.m. ET, featuring a fireside chat. The second event is at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, at 7:00 a.m. ET, with a corporate presentation. Live webcasts are available on the company's website and will be replayed for a limited time.

Prelude Therapeutics (Nasdaq: PRLD) reported a net loss of $26.9M for Q2 2021, equating to $0.58 per share, a significant increase from a net loss of $11.4M, or $5.50 per share, in Q2 2020. The company has $343.1M in cash for ongoing clinical trials, including Phase 1 studies of PRT543, PRT811, and PRT1419. Upcoming milestones include data presentations at the AACR-NCI-EORTC Annual Meeting. R&D expenses rose to $22.4M, driven by increased clinical research costs, while G&A expenses rose to $5.5M due to personnel growth and professional fees.